Latham & Watkins Advises NVIDIA on Investment in Recursion Pharmaceuticals

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, has announced a US$50 million investment by NVIDIA, which was executed as a private investment in public equity. Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.

Latham & Watkins LLP represented Recursion Pharmaceuticals in the investment with a corporate deal team led by a Bay Area partner Saad Khanani, with associate Natalie Robertson. Advice was also provided on capital markets matters by Los Angeles partner Greg Rodgers, with associate Kaj Nielsen; on healthcare regulatory matters by Washington, D.C. partner Ben Haas, with Washington, D.C. counsel Chad Jennings; and on IP matters by Bay Area partner Judith Hasko.